AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31784343 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine per pill)
Number of subjects: 400
Study 31784343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 30931709 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% silver nitrate (AgNO3) solution followed by a 5% sodium fluoride (NaF) varnish, semiannually (every 6 months)
Number of subjects: 1070
Study 30931709 — intervention group
Group type: COMPARATOR
Intervention: 38% silver diamine fluoride (SDF) solution followed by a placebo varnish, semiannually (every 6 months)
Number of subjects: 1070
Study 28295217 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic 270° posterior fundoplication (Toupet)
Number of subjects: 94
Study 28295217 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic 180° anterior fundoplication
Number of subjects: 94
Study 28295217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 94
Study 25976063 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100-µg i.v. bolus)
Number of subjects: 78
Study 25976063 — intervention group
Group type: COMPARATOR
Intervention: Intra-umbilical oxytocin (50 IU in 30 mL saline)
Number of subjects: 78
Study 25215305 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) subjects
Number of subjects: 94
Study 25215305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 94
Study 25215305 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with highest BMI in 2005
Number of subjects: 94
Study 22272740 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 300
Study 22272740 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarification Oriented Psychotherapy (COP)
Number of subjects: 300
Study 22272740 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 300
Study 20810312 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400mg)
Number of subjects: 19
Study 20810312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17139670 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 9404
Study 17139670 — intervention group
Group type: COMPARATOR
Intervention: Femoral access with sheath size 4 or 5 French (Fr)
Number of subjects: 9404
Study 17139670 — intervention group
Group type: COMPARATOR
Intervention: Femoral access with sheath size 6 Fr
Number of subjects: 9404
Study 17139670 — intervention group
Group type: COMPARATOR
Intervention: Femoral access with sheath size 7 Fr
Number of subjects: 9404
Study 17139670 — intervention group
Group type: COMPARATOR
Intervention: Femoral access with sheath size >or=8 Fr
Number of subjects: 9404
Study 17139670 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger sheath size and delayed sheath removal
Number of subjects: 9404
Study 15942511 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (2 mg)
Number of subjects: 72
Study 15942511 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone (0.15 mg/kg)
Number of subjects: 72
Study 12198600 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume liposuction
Number of subjects: 12
Study 9787368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2.0% dorzolamide and 0.5% timolol) administered twice daily
Number of subjects: 335
Study 9787368 — intervention group
Group type: COMPARATOR
Intervention: 2.0% dorzolamide administered three times daily
Number of subjects: 335
Study 9787368 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol administered twice daily
Number of subjects: 335
Study 7882126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFM)
Number of subjects: 23
Study 2297102 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (thiopental-nitrous oxide-halothane)
Number of subjects: 36
Study 2297102 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (0.5% bupivacaine)
Number of subjects: 36
Study 2297102 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with local anesthesia (infiltration of the abdominal wall with 0.25% bupivacaine)
Number of subjects: 36
Study 2297102 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 36
Study 2297102 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus local anesthesia
Number of subjects: 36
Study 2297102 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 36
Study 7392427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 96
Study 7392427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 7392427 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune complexes (detected by Clq-binding and Raji cell assays)
Number of subjects: 96
Study 7392427 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of immune complexes
Number of subjects: 96
Study 31968400 — intervention group
Group type: EXPERIMENTAL
Intervention: Allen Carr's Easyway (ACE)
Number of subjects: 620
Study 31968400 — intervention group
Group type: COMPARATOR
Intervention: Specialist stop smoking service (SSS)
Number of subjects: 620
Study 29943822 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling (SS arm) using the Rover VIBA-brush
Number of subjects: 19523
Study 29943822 — intervention group
Group type: COMPARATOR
Intervention: Assisted sampling (AS arm) using the cytobrush
Number of subjects: 19523
Study 29943822 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling (SS arm)
Number of subjects: 19523
Study 29943822 — intervention group
Group type: COMPARATOR
Intervention: Assisted sampling (AS arm)
Number of subjects: 19523
Study 27600055 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 843 mg of (−)-epigallocatechin-3-gallate (EGCG)
Number of subjects: 60
Study 27600055 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) with high COMT genotype
Number of subjects: 60
Study 27600055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27600055 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 60
Study 25869561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (Rho kinase inhibitor)
Number of subjects: 80
Study 25869561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 80
Study 24481886 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Early Intensive Cognitive Behavioral Intervention (TF-EICBI)
Number of subjects: 21
Study 24481886 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NEIG)
Number of subjects: 21
Study 17972445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with triclosan (n=28)
Number of subjects: 57
Study 17972445 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentifrice (n=29)
Number of subjects: 57
Study 15266215 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (10-80 mg daily)
Number of subjects: 7934
Study 15266215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective NSAIDs (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid)
Number of subjects: 7934
Study 15266215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7934
Study 15266215 — intervention group
Group type: EXPERIMENTAL
Intervention: Users of aspirin
Number of subjects: 7934
Study 15266215 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (therapeutic doses 10 or 20 mg daily and supratherapeutic doses 40 or 80 mg daily)
Number of subjects: 7934
Study 10781642 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 195
Study 10781642 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg/day)
Number of subjects: 195
Study 10781642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 8833557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention including diabetes education, medication counseling, dietary regulation, exercise, home blood glucose monitoring, and hypoglycemic regimen adjustment.
Number of subjects: 39
Study 8833557 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care provided by physicians (Control group).
Number of subjects: 39
Study 8833557 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist intervention vs Control group.
Number of subjects: 39
Study 8833557 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist intervention and Control group.
Number of subjects: 39
Study 1388954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit base
Number of subjects: 45
Study 1388954 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM base
Number of subjects: 45
Study 1388954 — intervention group
Group type: COMPARATOR
Intervention: No base
Number of subjects: 45
Study 3886357 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5mg three times daily
Number of subjects: 18
Study 3886357 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10mg three times daily
Number of subjects: 18
Study 31702056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg in 2 mL)
Number of subjects: 90
Study 31702056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg in 2 mL)
Number of subjects: 90
Study 31702056 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study 30137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 95
Study 30137218 — intervention group
Group type: COMPARATOR
Intervention: Weight Stability (WS)
Number of subjects: 95
Study 27884765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg, Naproxen 200 mg, Oseltamivir 75 mg twice daily for 2 days, followed by Oseltamivir 75 mg twice daily for 3 days
Number of subjects: 217
Study 27884765 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir 75 mg twice daily for 5 days (control)
Number of subjects: 217
Study 25881884 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 167
Study 25881884 — intervention group
Group type: COMPARATOR
Intervention: White Light Imaging
Number of subjects: 167
Study 23901667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (group 1)
Number of subjects: 100
Study 23901667 — intervention group
Group type: COMPARATOR
Intervention: No episiotomy (group 2)
Number of subjects: 100
Study 21367948 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (<20 g/d)
Number of subjects: 18
Study 21367948 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted diet (1200-1500 kcal/d)
Number of subjects: 18
Study 21367948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (carbohydrate and calorie restriction)
Number of subjects: 18
Study 19761358 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS) 0.8 U/kg
Number of subjects: 34
Study 19761358 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (G) 0.8 U/kg
Number of subjects: 34
Study 19761358 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (D) 0.8 U/kg
Number of subjects: 34
Study 17045796 — intervention group
Group type: COMPARATOR
Intervention: Continuous tamoxifen (40 mg daily)
Number of subjects: 276
Study 17045796 — intervention group
Group type: COMPARATOR
Intervention: Intermittent tamoxifen
Number of subjects: 276
Study 17045796 — intervention group
Group type: COMPARATOR
Intervention: Intermittent/alternated tamoxifen and medroxyprogesterone acetate (MPA, 300 mg daily)
Number of subjects: 276
Study 14751652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 14751652 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 32
Study 14751652 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 32
Study 14751652 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 32
Study 14751652 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 32
Study 10902257 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological testing for Bordetella pertussis
Number of subjects: 356
Study 10902257 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture confirmation of pertussis
Number of subjects: 356
Study 10902257 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of pertussis
Number of subjects: 356
Study 10902257 — intervention group
Group type: COMPARATOR
Intervention: Statutory notifications of pertussis
Number of subjects: 356
Study 9324165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK8; 12.5 pmol/kg x h)
Number of subjects: 10
Study 9324165 — intervention group
Group type: EXPERIMENTAL
Intervention: Yolk intake
Number of subjects: 10
Study 9324165 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA; 4.0 micromol/kg x h)
Number of subjects: 10
Study 9324165 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐arginine (1 mmol/kg x h)
Number of subjects: 10
Study 9324165 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 8453706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (3,750 mg/m2 on days 1 and 2 every 3 weeks) + Doxorubicin (30 mg/m2 for 2 days)
Number of subjects: 260
Study 8453706 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (80 mg/m2 every 3 weeks)
Number of subjects: 260
Study 8453706 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2) + Mitomycin (8 mg/m2) + Cisplatin (60 mg/m2, all given intravenously on day 1)
Number of subjects: 260
Study 2420444 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 122
Study 2420444 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM‐Reg (doxorubicin-containing regimen)
Number of subjects: 122
Study 2420444 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM‐Reg (MABOP)
Number of subjects: 122
Study 2420444 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM‐Reg (ABVD)
Number of subjects: 122
Study 2420444 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM‐Reg (MOPP alternated with ABVD)
Number of subjects: 122
Study 2420444 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM‐Reg
Number of subjects: 122
Study 2420444 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 122
Study 2420444 — intervention group
Group type: EXPERIMENTAL
Intervention: MABOP
Number of subjects: 122
Study 31899723 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprainguinal FICB with 30 mL of 0.375% ropivacaine
Number of subjects: 74
Study 31899723 — intervention group
Group type: COMPARATOR
Intervention: Infrainguinal FICB with 30 mL of 0.375% ropivacaine
Number of subjects: 74
Study 30536353 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 40
Study 30536353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25529756 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg day-1 ranitidine
Number of subjects: 75
Study 25529756 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg day-1 ranitidine
Number of subjects: 75
Study 25529756 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine only (control)
Number of subjects: 75
Study 24571704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilised, stannous fluoride (SnF2) dentifrice (1,100 ppm F as SnF2 + 350 ppm F as NaF)
Number of subjects: 12
Study 24571704 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) dentifrice (1,450 ppm F as NaF)
Number of subjects: 12
Study 24571704 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 12
Study 22847287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet potato/footbath/acupressure massage (SFA) intervention combined with usual care
Number of subjects: 93
Study 20226474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Number of subjects: 296
Study 20226474 — intervention group
Group type: COMPARATOR
Intervention: Forceps biopsy
Number of subjects: 296
Study 18400123 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary fall prevention program
Number of subjects: 333
Study 18400123 — intervention group
Group type: COMPARATOR
Intervention: Usual Dutch healthcare (control)
Number of subjects: 333
Study 16398970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 100
Study 12771323 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined olive oil (rich in monounsaturated fatty acids, n = 17)
Number of subjects: 48
Study 12771323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (rich in MUFA and alpha‐linolenic acid, n = 13)
Number of subjects: 48
Study 12771323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (rich in (n‐6) PUFA, n = 18)
Number of subjects: 48
Study 12771323 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet rich in saturated fatty acids
Number of subjects: 48
Study 10470628 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 30
Study 10470628 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane
Number of subjects: 30
Study 10470628 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane with nitrous oxide (N2O)
Number of subjects: 30
Study 8544269 — intervention group
Group type: EXPERIMENTAL
Intervention: GG167 (3.6 to 16 mg, administered intranasally two or six times daily)
Number of subjects: 166
Study 8544269 — intervention group
Group type: EXPERIMENTAL
Intervention: GG167 (early treatment)
Number of subjects: 166
Study 8544269 — intervention group
Group type: EXPERIMENTAL
Intervention: GG167 (other measures)
Number of subjects: 166
Study 8544269 — intervention group
Group type: EXPERIMENTAL
Intervention: GG167 (twice daily dosing)
Number of subjects: 166
Study 1704089 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous hydromorphone infusion
Number of subjects: 15
Study 1704089 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydromorphone infusion
Number of subjects: 15
Study 6884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg/day
Number of subjects: 32
Study 6884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (various doses: 90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg, 450 mg/day)
Number of subjects: 32
Study 6884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 32
Study 30362211 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic pressure (SuPuP) applied during hysteroscopy
Number of subjects: 60
Study 30362211 — intervention group
Group type: COMPARATOR
Intervention: No suprapubic pressure (control group)
Number of subjects: 60
Study 29273659 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 682
Study 29273659 — intervention group
Group type: COMPARATOR
Intervention: Open microdiscectomy
Number of subjects: 682
Study 29273659 — intervention group
Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 682
Study 29273659 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation from a societal perspective
Number of subjects: 682
Study 25651447 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer assistance during lunch meals
Number of subjects: 8
Study 25651447 — intervention group
Group type: COMPARATOR
Intervention: Days without volunteer assistance
Number of subjects: 8
Study 25448497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of atorvastatin calcium and methylprednisolone
Number of subjects: 38
Study 21733697 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg/kg tranexamic acid at induction of anaesthesia
Number of subjects: 66
Study 21733697 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of fibrin spray administered topically during surgery
Number of subjects: 66
Study 21733697 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving neither treatment
Number of subjects: 66
Study 19268281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment for tinnitus distress
Number of subjects: 19
Study 18019049 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies and pragmatic trials
Number of subjects: 0
Study 18019049 — intervention group
Group type: COMPARATOR
Intervention: Traditional RCTs
Number of subjects: 0
Study 15685837 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC100 regimen
Number of subjects: 0
Study 15685837 — intervention group
Group type: COMPARATOR
Intervention: FEC50 regimen
Number of subjects: 0
Study 15685837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per year of life saved
Number of subjects: 0
Study 11581083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispatcher assistance
Number of subjects: 150
Study 11581083 — intervention group
Group type: COMPARATOR
Intervention: No dispatcher assistance
Number of subjects: 150
Study 9513583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily for 8 weeks)
Number of subjects: 11
Study 7844297 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide bleaching gel (short application time)
Number of subjects: 24
Study 7844297 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide bleaching gel (extended application time)
Number of subjects: 24
Study 3132124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate
Number of subjects: 20
Study 3132124 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study 3132124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate (in patients with bleeding tendencies)
Number of subjects: 20
Study 3132124 — intervention group
Group type: COMPARATOR
Intervention: Heparin (in patients with bleeding tendencies)
Number of subjects: 20
Study 31379269 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (15 g of prebiotics, 5 g of probiotics containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA-6, Bifidobacterium lactis BIA-7, and Bifidobacterium longum BIA-8 (2.7×107 CFU/g each))
Number of subjects: 75
Study 31379269 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (5 g probiotics with 15 g of maltodextrin as placebo)
Number of subjects: 75